FDA Boxed Warning Removal on Menopause Hormone Therapy: What Geriatricians Should Know
- 12 December 2025
- journal article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (4) , 1210-1212
Abstract
A New Era for Menopause Hormone Therapy: Key Considerations for Geriatricians After FDA Boxed Warning Removal.Keywords
This publication has 15 references indexed in Scilit:
- Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor SymptomsJAMA Internal Medicine, 2025
- Enhancing quality of life: addressing vulvovaginal atrophy and urinary tract symptomsClimacteric, 2025
- Genitourinary Syndrome of MenopauseMedical Clinics of North America, 2023
- Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal PersonsJAMA, 2022
- Persistent gap in menopause care 20 years after the WHI: a population-based study of menopause-related symptoms and their managementMaturitas, 2022
- Improving management of the genitourinary syndrome of menopause: evaluation of a health system–based, cluster-randomized interventionAmerican Journal of Obstetrics and Gynecology, 2021
- Safety of vaginal estrogens: a systematic reviewMenopause, 2020
- Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort StudyMenopause, 2018
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific MortalityJAMA, 2017
- Vaginal Estrogen for Genitourinary Syndrome of MenopauseObstetrics & Gynecology, 2014